BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Davin JC, Strain L, Goodship TH. Plasma therapy in atypical haemolytic uremic syndrome: lessons from a family with a factor H mutation. Pediatr Nephrol 2008;23:1517-21. [PMID: 18483746 DOI: 10.1007/s00467-008-0833-y] [Cited by in Crossref: 35] [Cited by in F6Publishing: 30] [Article Influence: 2.5] [Reference Citation Analysis]
Number Citing Articles
1 Noris M, Remuzzi G. Genetics and Genetic Testing in Hemolytic Uremic Syndrome/Thrombotic Thrombocytopenic Purpura. Seminars in Nephrology 2010;30:395-408. [DOI: 10.1016/j.semnephrol.2010.06.006] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 1.9] [Reference Citation Analysis]
2 Zuber J, Le Quintrec M, Sberro-soussan R, Loirat C, Frémeaux-bacchi V, Legendre C. New insights into postrenal transplant hemolytic uremic syndrome. Nat Rev Nephrol 2011;7:23-35. [DOI: 10.1038/nrneph.2010.155] [Cited by in Crossref: 124] [Cited by in F6Publishing: 92] [Article Influence: 10.3] [Reference Citation Analysis]
3 Kim JJ, Goodship THJ, Tizard J, Inward C. Plasma therapy for atypical haemolytic uraemic syndrome associated with heterozygous factor H mutations. Pediatr Nephrol 2011;26:2073-6. [DOI: 10.1007/s00467-011-1944-4] [Cited by in Crossref: 24] [Cited by in F6Publishing: 16] [Article Influence: 2.2] [Reference Citation Analysis]
4 Ersoy Dursun F, Yesil G, Sasak G, Dursin H. Familial Atypical Hemolytic Uremic Syndrome with Positive p.S1191L (c.3572C>T) Mutation on the CFH Gene: A Single-center Experience. Balkan J Med Genet 2021;24:81-8. [PMID: 34447663 DOI: 10.2478/bjmg-2021-0007] [Reference Citation Analysis]
5 Kavanagh D, Goodship TH. Atypical hemolytic uremic syndrome, genetic basis, and clinical manifestations. Hematology Am Soc Hematol Educ Program. 2011;2011:15-20. [PMID: 22160007 DOI: 10.1182/asheducation-2011.1.15] [Cited by in Crossref: 50] [Cited by in F6Publishing: 39] [Article Influence: 5.0] [Reference Citation Analysis]
6 Alasfar S, Alachkar N. Atypical hemolytic uremic syndrome post-kidney transplantation: two case reports and review of the literature. Front Med (Lausanne) 2014;1:52. [PMID: 25593925 DOI: 10.3389/fmed.2014.00052] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
7 Noris M, Remuzzi G. Managing and preventing atypical hemolytic uremic syndrome recurrence after kidney transplantation. Curr Opin Nephrol Hypertens. 2013;22:704-712. [PMID: 24076560 DOI: 10.1097/mnh.0b013e328365b3fe] [Cited by in Crossref: 40] [Cited by in F6Publishing: 21] [Article Influence: 5.0] [Reference Citation Analysis]
8 Zhang K, Lu Y, Harley KT, Tran MH. Atypical Hemolytic Uremic Syndrome: A Brief Review. Hematol Rep 2017;9:7053. [PMID: 28626544 DOI: 10.4081/hr.2017.7053] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 5.2] [Reference Citation Analysis]
9 Aigner C, Böhmig GA, Eskandary F, Herkner H, Prohászka Z, Csuka D, Kain R, Gaggl M, Sunder-Plassmann R, Müller-Sacherer T, Oszwald A, Fischer G, Schmidt A, Sunder-Plassmann G. Preemptive plasma therapy prevents atypical hemolytic uremic syndrome relapse in kidney transplant recipients. Eur J Intern Med 2020;73:51-8. [PMID: 31791575 DOI: 10.1016/j.ejim.2019.11.007] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
10 Davin JC, van de Kar NC. Advances and challenges in the management of complement-mediated thrombotic microangiopathies. Ther Adv Hematol 2015;6:171-85. [PMID: 26288712 DOI: 10.1177/2040620715577613] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
11 Yenerel MN. Atypical Hemolytic Uremic Syndrome: Differential Diagnosis from TTP/HUS and Management. Turk J Haematol 2014;31:216-25. [PMID: 25319590 DOI: 10.4274/tjh.2013.0374] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
12 Wilson C, Torpey N, Jaques B, Strain L, Talbot D, Manas D, Goodship T. Successful simultaneous liver-kidney transplant in an adult with atypical hemolytic uremic syndrome associated with a mutation in complement factor H. Am J Kidney Dis 2011;58:109-12. [PMID: 21601332 DOI: 10.1053/j.ajkd.2011.04.008] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 1.5] [Reference Citation Analysis]
13 Barbour T, Johnson S, Cohney S, Hughes P. Thrombotic microangiopathy and associated renal disorders. Nephrol Dial Transplant. 2012;27:2673-2685. [PMID: 22802583 DOI: 10.1093/ndt/gfs279] [Cited by in Crossref: 121] [Cited by in F6Publishing: 93] [Article Influence: 12.1] [Reference Citation Analysis]
14 Noris M, Remuzzi G. Thrombotic microangiopathy after kidney transplantation. Am J Transplant. 2010;10:1517-1523. [PMID: 20642678 DOI: 10.1111/j.1600-6143.2010.03156.x] [Cited by in Crossref: 132] [Cited by in F6Publishing: 110] [Article Influence: 11.0] [Reference Citation Analysis]
15 De S, Waters AM, Segal AO, Trautmann A, Harvey EA, Licht C. Severe atypical HUS caused by CFH S1191L--case presentation and review of treatment options. Pediatr Nephrol 2010;25:97-104. [PMID: 19856002 DOI: 10.1007/s00467-009-1306-7] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.3] [Reference Citation Analysis]
16 Davin JC, Buter N, Groothoff J, van Wijk J, Bouts A, Strain L, Goodship T. Prophylactic plasma exchange in CD46-associated atypical haemolytic uremic syndrome. Pediatr Nephrol 2009;24:1757-60. [PMID: 19373492 DOI: 10.1007/s00467-009-1188-8] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 1.7] [Reference Citation Analysis]
17 Noris M, Remuzzi G. Thrombotic microangiopathy: what not to learn from a meta-analysis. Nat Rev Nephrol 2009;5:186-8. [PMID: 19322181 DOI: 10.1038/nrneph.2009.28] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
18 Zuber J, Le Quintrec M, Morris H, Frémeaux-Bacchi V, Loirat C, Legendre C. Targeted strategies in the prevention and management of atypical HUS recurrence after kidney transplantation. Transplant Rev (Orlando). 2013;27:117-125. [PMID: 23937869 DOI: 10.1016/j.trre.2013.07.003] [Cited by in Crossref: 56] [Cited by in F6Publishing: 51] [Article Influence: 6.2] [Reference Citation Analysis]
19 Al-Akash SI, Almond PS, Savell VH, Gharaybeh SI, Hogue C. Eculizumab induces long-term remission in recurrent post-transplant HUS associated with C3 gene mutation. Pediatr Nephrol. 2011;26:613-619. [PMID: 21125405 DOI: 10.1007/s00467-010-1708-6] [Cited by in Crossref: 76] [Cited by in F6Publishing: 67] [Article Influence: 6.3] [Reference Citation Analysis]
20 de Wit Y, Rethans A, van Mierlo G, Wouters D, ten Brinke A, Bemelman FJ, Zeerleder S. Plasma Exchange Therapy Using Solvent Detergent-Treated Plasma: An Observational Pilot Study on Complement, Neutrophil and Endothelial Cell Activation in a Case Series of Patients Suffering from Atypical Hemolytic Uremic Syndrome. Transfus Med Hemother. [DOI: 10.1159/000522137] [Reference Citation Analysis]
21 Davin JC, Gracchi V, Bouts A, Groothoff J, Strain L, Goodship T. Maintenance of kidney function following treatment with eculizumab and discontinuation of plasma exchange after a third kidney transplant for atypical hemolytic uremic syndrome associated with a CFH mutation. Am J Kidney Dis 2010;55:708-11. [PMID: 19854549 DOI: 10.1053/j.ajkd.2009.08.011] [Cited by in Crossref: 81] [Cited by in F6Publishing: 77] [Article Influence: 6.2] [Reference Citation Analysis]
22 Loirat C, Frémeaux-Bacchi V. Atypical hemolytic uremic syndrome. Orphanet J Rare Dis 2011;6:60. [PMID: 21902819 DOI: 10.1186/1750-1172-6-60] [Cited by in Crossref: 375] [Cited by in F6Publishing: 304] [Article Influence: 34.1] [Reference Citation Analysis]
23 Davin JC, Groothoff J, Gracchi V, Bouts A. Long-term renal function under plasma exchange in atypical hemolytic uremic syndrome. Pediatr Nephrol 2011;26:1915-6. [PMID: 21647646 DOI: 10.1007/s00467-011-1925-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
24 Noris M, Caprioli J, Bresin E, Mossali C, Pianetti G, Gamba S, Daina E, Fenili C, Castelletti F, Sorosina A, Piras R, Donadelli R, Maranta R, van der Meer I, Conway EM, Zipfel PF, Goodship TH, Remuzzi G. Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol. 2010;5:1844-1859. [PMID: 20595690 DOI: 10.2215/cjn.02210310] [Cited by in Crossref: 584] [Cited by in F6Publishing: 274] [Article Influence: 48.7] [Reference Citation Analysis]
25 Tran H, Chaudhuri A, Concepcion W, Grimm PC. Use of eculizumab and plasma exchange in successful combined liver-kidney transplantation in a case of atypical HUS associated with complement factor H mutation. Pediatr Nephrol 2014;29:477-80. [PMID: 24221349 DOI: 10.1007/s00467-013-2630-5] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.8] [Reference Citation Analysis]
26 Chua S, Wong G, Lim WH. The importance of genetic mutation screening to determine retransplantation following failed kidney allograft from recurrent atypical haemolytic ureamic syndrome. BMJ Case Rep. 2014;2014:pii: bcr2013202875. [PMID: 24671321 DOI: 10.1136/bcr-2013-202875] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
27 Loirat C, Macher MA, Elmaleh-Berges M, Kwon T, Deschênes G, Goodship TH, Majoie C, Davin JC, Blanc R, Savatovsky J, Moret J, Fremeaux-Bacchi V. Non-atheromatous arterial stenoses in atypical haemolytic uraemic syndrome associated with complement dysregulation. Nephrol Dial Transplant 2010;25:3421-5. [PMID: 20530807 DOI: 10.1093/ndt/gfq319] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 1.9] [Reference Citation Analysis]
28 Geerdink LM, Westra D, van Wijk JA, Dorresteijn EM, Lilien MR, Davin JC, Kömhoff M, Van Hoeck K, van der Vlugt A, van den Heuvel LP, van de Kar NC. Atypical hemolytic uremic syndrome in children: complement mutations and clinical characteristics. Pediatr Nephrol 2012;27:1283-91. [PMID: 22410797 DOI: 10.1007/s00467-012-2131-y] [Cited by in Crossref: 91] [Cited by in F6Publishing: 80] [Article Influence: 9.1] [Reference Citation Analysis]
29 Boyer O, Niaudet P. Hemolytic uremic syndrome: new developments in pathogenesis and treatment. Int J Nephrol 2011;2011:908407. [PMID: 21876803 DOI: 10.4061/2011/908407] [Cited by in Crossref: 31] [Cited by in F6Publishing: 17] [Article Influence: 2.8] [Reference Citation Analysis]
30 Loirat C, Saland J, Bitzan M. Management of hemolytic uremic syndrome. Presse Med. 2012;41:e115-e135. [PMID: 22284541 DOI: 10.1016/j.lpm.2011.11.013] [Cited by in Crossref: 69] [Cited by in F6Publishing: 45] [Article Influence: 6.9] [Reference Citation Analysis]
31 Brown JH, Tellez J, Wilson V, Mackie IJ, Scully M, Tredger MM, Moore I, McDougall NI, Strain L, Marchbank KJ, Sheerin NS, O'Grady J, Harris CL, Goodship TH. Postpartum aHUS secondary to a genetic abnormality in factor H acquired through liver transplantation. Am J Transplant 2012;12:1632-6. [PMID: 22420623 DOI: 10.1111/j.1600-6143.2012.03991.x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
32 Davin JC, Majoie C, Groothoff J, Gracchi V, Bouts A, Goodship TH, Loirat C. Prevention of large-vessel stenoses in atypical hemolytic uremic syndrome associated with complement dysregulation. Pediatr Nephrol 2011;26:155-7. [PMID: 20652819 DOI: 10.1007/s00467-010-1608-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]